Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

Patients who provide written informed consent to participate in the study
Male and female patients with ≥18 years of age
Diagnosis of clinically unequivocal moderate to severe HS
Patients for whom a therapy with secukinumab is medically indicated
Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
Treatment with secukinumab according to the latest version of SmPC
Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
Previous exposure to IL-17 inhibitors
For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors